Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05888961 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Single-center Prospective Longitudinal Study of Taste in Patients With Cognitive Disorders at Different Stages of Severity (Isolated Cognitive Complaint, Minor or Major Neurocognitive Alzheimer-type Disorders) by Analysis of Gustatory Evoked Potentials

Study acronym: MAPEG 2
StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 4 months later Jul 2027 → Dec 2027
See other at-risk trials from Centre Hospitalier Universitaire Dijon

Record History

  1. Primary and study completion pushed from Jul 2027 to Dec 2027 Enrollment target: 72 to 74 · Eligibility criteria expanded, about 22 words Show 2 more changesShow less
    • Enrollment target: 72 to 74
    • Eligibility criteria expanded, about 22 words
  2. Primary and study completion dates: Jul 2026 to Jul 2027v4
  3. Enrollment target: 125 to 72 Eligibility criteria shortened, about 28 words · Study arms: 5 to 4v3 Show 2 more changesShow less
    • Eligibility criteria shortened, about 28 words
    • Study arms: 5 to 4

    See this version in full on ClinicalTrials.gov ↗

  4. Trial status: Not Yet Recruiting to Recruiting Study sites: 0 to 1 · Primary and study completion dates: Jun 2026 to Jul 2026 · Start date changed from estimate of Jun 2023 to Jun 12, 2023v2 Show 3 more changesShow less
    • Study sites: 0 to 1
    • Primary and study completion dates: Jun 2026 to Jul 2026
    • Start date changed from estimate of Jun 2023 to Jun 12, 2023
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The aim of the MAPEG 2 study is to explore gustatory function and to follow its evolution in the 4 following groups of participants: * Healthy subjects * Participants with isolated cognitive complaint * Participants with minor neurocognitive disorder * Participants with mild and moderate Alzheimer-type major neurocognitive disorders For this purpose, we want to compare the results of the following tests: * Subjective taste tests (tasting solutions, answering food preference questionnaires), * Gustatory evoked potential (GEP) parameters, recorded by electrodes placed on the scalp, * And nutritional parameters (hormones of food intake by blood test, measurement of the global body composition). Identifying and following the evolution of early taste disorders in case of cognitive disorders could improve the diagnosis of Alzheimer\'s disease in two ways: * To allow an early diagnosis of Alzheimer\'s disease, and thus improve its management, * To define groups of subjects at risk of developing Alzheimer\'s disease in later years.
Trial Details
NCT Number NCT05888961
Lead Sponsor Centre Hospitalier Universitaire Dijon
Conditions Cognitive Disorders
Enrollment 74 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov